vosoritide
Phase 2Active 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Achondroplasia
Conditions
Achondroplasia
Trial Timeline
Oct 10, 2020 → Dec 1, 2027
NCT ID
NCT04554940About vosoritide
vosoritide is a phase 2 stage product being developed by BioMarin Pharmaceutical for Achondroplasia. The current trial status is active. This product is registered under clinical trial identifier NCT04554940. Target conditions include Achondroplasia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07073014 | Phase 3 | Recruiting |
| NCT04554940 | Phase 2 | Active |
Competing Products
20 competing products in Achondroplasia